Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep683 | Pituitary and Neuroendocrinology | ECE2020

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH- and GH-secreting pituitary neuroendocrine tumor cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Maria Clara Alvarez Villamarin , Dieguez Carlos , Zatelli Chiara , Cannavò Salvatore , Grottoli Silvia , Arvat Emanuela , Castaño Justo P. , Luque Raùl M. , Cai Renzhi , Sha Wei , Victor Schally Andrew , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETscan be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resectionis the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are pr...

ea0022p621 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Decreased cortical thickness on MRI in patients with Cushing's syndrome: preliminary experience

Santos Alicia , Granell Esther , Resmini Eugenia , Ybarra Juan , Portella Maria J , Perez Victor , Barahona Maria J , Mourelo Olga Lopez , Vives Yolanda , De Juan Manuel , Pires Patricia , Gomez Anson Beatriz , Webb Susan

Introduction: Patients with Cushing’s syndrome might present a variety of brain alterations. There is however little evidence from MRI studies demonstrating atrophy of either frontal or medial temporal brain regions.Aims: To study cortical alterations (decreased cortical thickness) on MRI in patients with Cushing’s syndrome (CS), as compared to controls (C), and long-standing major depressive disorder (MDD).Material and m...

ea0020p169 | Thyroid | ECE2009

Frequency of thyroid function test abnormalities in an open population in Queretaro, Mexico

Osorio Ma. Ludivina Robles , Montiel Hebert Luis Hernandez , Sainz Juan Carlos Solis , Solis Pablo Garcia , Silva Ernesto Francisco Sabath , Lomeli Adrian Hernandez , Maya Victor Eduardo , Ramirez Nestor , Gonzalez David , Alcantara Alejandro

It is important to know the prevalence of common diseases in every country in order to guide us to take decisions regarding public health benefits in screening, in Mexico we do not have information regarding thyroid abnormalities.Methods: We designed a cross-sectional study in the city of Queretaro (Mexico) in order to know the prevalence of altered thyroid function tests in our population, since we do not have any previous study. We calculated the sampl...

ea0081ep1190 | Late Breaking | ECE2022

NanoLuc® Binary Technology to explore the mechanism of action of a Magmas inhibitor

Borges de Souza Patricia , Gagliardi Irene , Ambrosio Maria Rosaria , Bondanelli Marta , Zatelli Maria Chiara

Introduction: Magmas encodes for an integral constituent of the TIM23 translocase complex located in the mitochondrial inner membrane that drives proteins from the intermembrane space into the mitochondrial matrix by functionally interacting with Tim14. We previously demonstrated that Magmas silencing is able to sensitize ACTH-secreting mouse pituitary adenoma cells to pro-apoptotic stimuli, reduce DNA synthesis, accumulate cells in G0/G1 phase with concomitant decrease in S p...

ea0063gp102 | Adrenal and Neuroendocrine - Basic | ECE2019

Development of a simple experiment to distinguish ARMC5 missense mutants from rare ARMC5 polymorphisms in PBMAH patients using a quantitative western blot approach

Vaczlavik Anna , Espiard Stephanie , Ribes Christopher , North Marie-Odile , Drougat Ludivine , Ragazzon Bruno , Rizk-Rabin Marthe , Bertherat Jerome

Introduction: Germline inactivating ARMC5 (Armadillo repeat containing 5) mutations are responsible for Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH). ARMC5 presents the characteristics of a tumor suppressor gene. Mutations are observed in more than 85% of patients with a clear familial presentation and 20 to 25% of apparently sporadic cases. Genetic alterations are spread all over ARMC5 coding sequence and more than two-third of them ar...

ea0055p34 | Poster Presentations | SFEEU2018

Hyperkalaemia in Conn’s syndrome masking hyporeninaemic hypoaldosteronism

Rogers Rebecca , Burgess Neil , Ross Calum , Myint Kwin Swe

Background: Primary hyperaldosteronism (PHA) typically manifests as resistant hypertension, hypokalaemia and metabolic alkalosis. We present a case of PHA who subsequently exposed type 4 renal tubular acidosis (RTA) after surgical intervention.Case history: A 62 year old man underwent investigation for chronic resistant hypertension, which had failed to respond to titration of three antihypertensive agents including Perindopril, Amlodipine and Doxazosin....

ea0081ep385 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Adult-onset loss of the hepatocyte growth hormone receptor (GHR) is associated with increased autophagy in livers of male mice in the context of natural daytime fasting

Sarmento-Cabral Andre , Gutierrez-Casado Elena , del Rio-Moreno Mercedes , Vazquez-Borrego Mari C , Kineman Rhonda D

Liver autophagy, as assessed by accumulation of LC3-II and p62 proteins, is positively correlated with the severity of nonalcoholic steatohepatitis (NASH) in humans. Since growth hormone (GH) is negatively associated with liver steatosis and NASH development, and our laboratory has reported that steatosis and NASH develops in a mouse model of adult-onset, hepatocyte-specific GH-Receptor knockdown (aHepGHRkd), we sought to determine if GH directly regulates the hepatocyte autop...

ea0050oc6.3 | Bone, Calcium and Neoplasia | SFEBES2017

Generation of multiple endocrine neoplasia type 1 and death-domain-associated protein pluripotent stem cell lines to investigate mechanisms of pancreatic neuroendocrine tumourigenesis

Dissanayake Kumara , Davidson Lindsay , Poland Conor , Newey Paul

Background: Despite a wealth of gene-discovery studies identifying recurrently mutated genes in hereditary and sporadic endocrine tumours, the molecular mechanisms underpinning tumourigenesis frequently remain ill-defined, in part reflecting a lack of physiologically relevant model systems to investigate gene function. Here, using pancreatic neuroendocrine tumours as an example, we explored the utility of human induced pluripotent stem cell (iPSCs) and CRISPR/Cas9 gene-editing...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0050oc6.3 | Bone, Calcium and Neoplasia | SFEBES2017

Generation of multiple endocrine neoplasia type 1 and death-domain-associated protein pluripotent stem cell lines to investigate mechanisms of pancreatic neuroendocrine tumourigenesis

Dissanayake Kumara , Davidson Lindsay , Poland Conor , Newey Paul

Background: Despite a wealth of gene-discovery studies identifying recurrently mutated genes in hereditary and sporadic endocrine tumours, the molecular mechanisms underpinning tumourigenesis frequently remain ill-defined, in part reflecting a lack of physiologically relevant model systems to investigate gene function. Here, using pancreatic neuroendocrine tumours as an example, we explored the utility of human induced pluripotent stem cell (iPSCs) and CRISPR/Cas9 gene-editing...